in-house crispr counting algorithm (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
in-house crispr counting algorithm
In House Crispr Counting Algorithm, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/in-house+algorithm/in+house+crispr+counting+algorithm/pmc11863645-159-30-29
Average 90 stars, based on 1 article reviews
In House Crispr Counting Algorithm, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/in-house+algorithm/in+house+crispr+counting+algorithm/pmc11863645-159-30-29
Average 90 stars, based on 1 article reviews
in-house crispr counting algorithm - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 Article Snippet: Small molecule activators of the glucokinase enzyme have the potential to deliver a level of glycaemic control that is superior to current oral agents and hence have great promise as new therapies for Type 2 Diabetes.. As such, attempts to discover glucokinase activators suitable for clinical development have been the focus of many major pharmaceutical research programmes.. Here we show how propertybased matrix optimisation has been used to improve the multi-parameter technical profile of the AstraZeneca series of glucokinase activators culminating in the discovery of the development candidate AZD1092. CRISPR:Article Title: A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiency Article Snippet: For each CRISPR pooled screen, DNA sequencing data was generated by either the Illumina HiSeq 4000 or NovaSeq 6000 platforms and FASTQ files were produced using bcl2fastq2. .. The reads were cross-referenced against the relevant gRNA library sequences and exact matches were counted to produce a gRNA count matrix (gRNAs as rows, samples as columns) using an Permeability:Article Title: A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Article Snippet: Accepted Manuscript A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy Lei Yin, Heng Li, Wenjian Liu, Zhenglin Yao, Zhenzhen Cheng, Huabei Zhang, Hui Zou PII: S0223-5234(17)31009-7 DOI: 10.1016/j.ejmech.2017.12.003 Reference: EJMECH 9981 To appear in: European Journal of Medicinal Chemistry Received Date: 1 November 2017 Revised Date: 29 November 2017 Accepted Date: 1 December 2017 Please cite this article as: L. Yin, H. Li, W. Liu, Z. Yao, Z. Cheng, H. Zhang, H. Zou, A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy, European Journal of Medicinal Chemistry (2018), doi: 10.1016/j.ejmech.2017.12.003.. This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript. |